The natural history of progressive fibrosing interstitial lung diseases
A proportion of patients with certain types of interstitial lung disease (ILD), including chronic hypersensitivity pneumonitis and ILDs associated with autoimmune diseases, develop a progressive fibrosing phenotype that shows similarities in clinical course to idiopathic pulmonary fibrosis. Irrespective of the clinical diagnosis, these progressive fibrosing ILDs show commonalities in the underlying pathogenetic mechanisms that drive a self-sustaining process of pulmonary fibrosis. The natural history of progressive fibrosing ILDs is characterized by decline in lung function, worsening of symptoms and health-related quality of life, and early mortality. Greater impairment in forced vital capacity or diffusion capacity of the lungs for carbon monoxide, and a greater extent of fibrotic changes on a computed tomography scan, are predictors of mortality in patients with fibrosing ILDs. However, the course of these diseases is heterogenous and cannot accurately be predicted for an individual patient. Data from ongoing clinical trials and patient registries will provide a better understanding of the clinical course and impact of progressive fibrosing ILDs.
KeywordsPulmonary fibrosis Connective tissue diseases Rheumatic diseases Systemic sclerosis Vital capacity Mortality
Connective tissue disease-related ILDs
Diffusion capacity of the lungs for carbon monoxide
European League Against Rheumatism
EULAR Scleroderma Trials and Research group
Forced vital capacity
Interstitial lung disease
Idiopathic non-specific interstitial pneumonia
Interstitial pneumonia with autoimmune features
Idiopathic pulmonary fibrosis
Rheumatoid arthritis ILD
Systemic sclerosis ILD
Usual interstitial pneumonia
Pathogenesis of progressive fibrosing ILDs
Some ILDs are primarily considered fibro-proliferative disorders, in which alveolar epithelial injury and fibroblastic proliferation lead to fibrosis, while other ILDs are considered primarily inflammatory disorders in which the pathogenic process shifts to a fibro-proliferative pathway under certain conditions [13, 14]. Regardless of the trigger, fibrosing ILDs show commonalities in the mechanisms involved in their pathogenesis and progression. Repeated chronic epithelial or vascular injuries lead to cell destruction and to unregulated repair [15, 16, 17]. Fibroblasts proliferate, migrate from different sources to the site of injury and are activated to become myofibroblasts, which secrete increased amounts of extracellular matrix. This, together with reduced matrix degradation, results in increased tissue stiffness and loss of function of the alveolar tissue [18, 19, 20, 21, 22]. Macrophages and lymphocytes are recruited to the site of injury and release pro-fibrotic mediators that further promote fibroblast activation . In a feed-forward loop, the increased lung tissue stiffness further activates and stimulates fibroblasts to drive a self-sustaining process of fibrosis [23, 24]. As an increasing extent of the lung is lost to fibrosis, the volume of the lung is reduced and gas exchange impaired, resulting in worsening breathlessness and capacity for exertion, and ultimately in respiratory failure.
Lung function decline in progressive fibrosing ILDs
Although some patients with chronic HP experience partial recovery, patients with chronic fibrosing HP may experience rapid disease progression, particularly if the inciting antigen cannot be identified and removed [32, 33]. In a recent longitudinal cohort analysis, the monthly decline in FVC % predicted over 1 year in 119 patients with chronic HP was similar to that of 286 patients with IPF . In patients with stage IV pulmonary sarcoidosis, both increases and decreases in FVC and DLco may be observed over time as the disease relapses and remits . Little is known about the clinical course of fibrotic iNSIP, but it seems to progress more slowly than other forms of fibrosing ILD .
Acute exacerbations of fibrosing ILDs
Acute exacerbations - episodes of rapid respiratory worsening accompanied by evidence of new ground glass opacities on HRCT - are a common feature of the natural history of IPF, believed to occur in 5–10% of patients per year . Acute exacerbations of IPF may be idiopathic or triggered by an insult such as infection or aspiration. Irrespective of their cause, acute exacerbations of IPF are associated with very high morbidity and mortality, with a median post-event survival of only 3 to 4 months . Far fewer data are available on acute exacerbations of fibrosing ILDs other than IPF, and most come from retrospective reviews of medical records. However, it appears that acute exacerbations do occur in patients with fibrosing ILDs other than IPF and are often fatal. An analysis of medical records from 84 patients with RA-ILD from two tertiary referral centers found that 14 patients (17%) had an idiopathic acute exacerbation over a median follow-up of 33 months, and 13 of those 14 patients died within 1.5 months of the event . A study of 51 patients with RA-ILD at another center found that 22% had an acute exacerbation over a follow-up period of about 8 years . In patients with SSc-ILD, acute exacerbations appear to be more common in patients with a usual interstitial pneumonia (UIP) pattern on computed tomography or histology [40, 41]. A study of 100 patients with chronic HP found that 14 patients were hospitalized for an acute exacerbation over a 2-year period, of whom 11 died within one month; patients with a UIP pattern on histology were more likely to experience acute exacerbations than those with other patterns .
Mortality in patients with progressing fibrosing ILDs
Progressive fibrosing ILDs are associated with high mortality. In patients with IPF who are not receiving an antifibrotic therapy, median post-diagnosis survival is 3–4 years [43, 44, 45]. ILD is one of the leading causes of death in patients with SSc . Estimates of survival time vary depending on the population studied, but a recent study of patients at a specialized SSc-ILD clinic found that median survival was 11.2 years from the date of the first HRCT showing evidence of ILD . RA-ILD is also associated with high mortality, particularly in patients with a UIP pattern on HRCT [47, 48, 49]. A retrospective analysis of 82 patients with RA-ILD at two tertiary referral centers found a median survival time of 5 years from the initial clinic visit (3.2 years in patients with a UIP pattern on HRCT) . Patients with features consistent with the research construct known as interstitial pneumonia with autoimmune features (IPAF), i.e., who have interstitial pneumonia with features suggestive of an autoimmune disease but do not meet criteria for a defined disease  appear to have a mortality rate that is intermediate between patients with IPF and CTD-ILDs . Fibrotic HP has a poor prognosis. A recent analysis of US claims data found that only 58% of patients with fibrotic HP were still alive approximately 7 years after diagnosis . Fibrotic iNSIP appears to have a better prognosis than other forms of progressive fibrosing ILD: considering only disease-related death, 5-year survival is approximately 75% . Assessment of the mortality associated with unclassifiable IIP is hampered by the wide variability in case definition across studies, but a systematic literature review found estimates for 5-year survival in patients with unclassifiable ILD, based on four studies of 46 to 70% .
Predictors of disease progression in patients with fibrosing ILDs
Studies in patients with progressive fibrosing ILDs have identified several factors that predict mortality, but these need to be interpreted carefully given the variation in the methodology used and the retrospective nature of most of the studies. Lower FVC is an established predictor of mortality in patients with progressive fibrosing ILDs, as evidenced by numerous studies spanning IPF [55, 56, 57], RA-ILD [4, 49], SSc-ILD [58, 59, 60], chronic HP [61, 62] and fibrotic iNSIP . The same is true of DLco [55, 56, 60, 63, 64, 65], although this is harder to assess in multi-center studies due to a lack of standardization in its measurement. A decline in FVC > 10% predicted is another well-established predictor of mortality [49, 56, 62, 65], but smaller declines in FVC have also been shown to be associated with a worse prognosis, at least in patients with IPF [66, 67, 68]. Further, it is important to bear in mind that “small” annual declines in FVC may become substantial when summed over a period of years. This is particularly relevant when considering ILDs with a relatively early age of onset.
Composite scoring systems have been developed to predict mortality in patients with progressive fibrosing ILDs. One of the most widely used is the GAP (gender, age, physiology) model, which was developed to predict mortality in patients with IPF based on gender, age, FVC % predicted and DLco % predicted , and has since been shown to predict mortality in patients with RA-ILD , SSc-ILD , unclassifiable ILD  and a mixed cohort . Composite scoring systems have also been developed specifically for prediction of progression of SSc-ILD [74, 75]. Unfortunately, none of the scoring systems developed to date provides an accurate prediction of the way that ILD will progress in an individual patient, creating challenges for therapeutic decision-making and patient counselling. Recently a cluster analysis in a cohort of 770 patients with diverse ILDs (IPF, CTD-ILDs, chronic HP, IPAF) identified four phenotypic groups based on factors such as age, race, smoking, and radiological features that differed in FVC decline and survival . Whilst interesting from an academic perspective, the use of such groupings in clinical practice remains to be established.
There is increasing interest in the use of radiological markers as predictors of disease progression in patients with fibrosing ILDs. A greater extent of fibrotic changes on HRCT is known to be predictive of mortality. This has been demonstrated in several studies in IPF , RA-ILD [48, 77], SSc-ILD [5, 58], chronic HP [61, 78], pulmonary sarcoidosis  and unclassifiable ILD . In addition, specific radiological features such as honeycombing and traction bronchiectasis have been associated with worse prognosis [33, 80]. However, the use of radiological scoring systems as predictors of prognosis in clinical practice is hampered by subjectivity and large inter-observer variability in reading HRCT scans, and will probably not be widely implemented until validated, low-cost, automated scoring systems are available .
Several blood biomarkers have been investigated as predictors of disease progression in patients with fibrosing ILDs. These include Krebs von den Lungen-6 protein (KL-6), which has been associated with a higher rate of disease progression in patients with IPF and CTD-ILDs [82, 83, 84, 85], and surfactant protein-D (SP-D) [86, 87]. Several studies have shown that levels of matrix metalloproteinase-7 (MMP-7), an enzyme involved in remodeling of the extracellular matrix, are negatively correlated with lung function and survival in patients with IPF [88, 89, 90, 91]. Protein fragments generated by breakdown of the extracellular matrix have also been investigated as predictors of disease progression [92, 93]. To date, however, no serum biomarker has been shown to be a sufficiently robust prognostic marker to justify its use in clinical practice, although KL-6 is routinely used at some ILD centers in Japan.
Genetic mutations and telomere length have also been investigated as predictors of disease progression in patients with fibrosing ILDs. In patients with IPF, rs35705950, the minor allele of a single nucleotide polymorphism (SNP) in MUC5B, a gene encoding a component of mucus secretions, has been associated with improved survival  while rs5743890, the minor allele of an SNP of TOLLIP (toll interacting protein), has been associated with worse survival . However, in patients with chronic HP, neither of these alleles was associated with survival . In patients with features consistent with IPAF, MUC5B rs35705950 was associated with worse survival, while there was no association between TOLLIP genotype and survival . Recently, MUC5B rs35705950 was associated with the development of RA-ILD . In addition, mutations in several genes related to telomere maintenance, such as telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC), have been identified in patients with IPF , and patients with short telomeres have reduced survival [100, 101]. Short telomere length has also been associated with worse survival in patients with features consistent with IPAF  and in patients with chronic HP . Variants in telomere-related genes have been identified in patients with RA-ILD  and SSc-ILD , but further investigation is needed into the association between these variants and the development and progression of ILD.
Further research into the natural history of progressive fibrosing ILDs
Data from clinical trials of investigational therapies made a large contribution to our understanding of the clinical course of IPF . Ongoing large clinical trials conducted in patients with non-IPF fibrosing ILDs [105, 106, 107, 108] will provide valuable insights into the progression of these diseases in well-characterized populations. In addition, the natural history of fibrosing ILDs is being investigated in many patient registries including the Pulmonary Fibrosis Foundation Patient Registry  and IPF-PRO/ILD-PRO Registry  in the USA, the Canadian Registry for Pulmonary Fibrosis (CARE-PF) , the INSIGHTS-IPF  and EXCITING-ILD  registries in Germany, and the EMPIRE registry in central and Eastern Europe . These and other registries will provide valuable information on the course of fibrosing ILDs diagnosed and managed in clinical practice, including their impact on lung function, patient-reported outcomes, hospitalizations and mortality. In addition, further research is needed into the impact that comorbidities such as pulmonary hypertension and ischemic heart disease have on outcomes in patients with ILDs .
A proportion of patients with fibrosing ILDs develop a progressive fibrosing phenotype that is similar to IPF in clinical behavior and in many of the underlying pathogenetic mechanisms that drive a self-sustaining process of pulmonary fibrosis. The natural history of progressive fibrosing ILDs is characterized by deterioration in lung function, worsening dyspnea and high mortality. A greater extent of fibrosis on HRCT and decline in lung function are predictors of mortality, but the course of disease for an individual patient cannot accurately be predicted using the currently available tools. Ongoing research will provide a better understanding of the clinical course of progressive fibrosing ILDs and their impact on patients.
Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Elizabeth Ng and Wendy Morris of FleishmanHillard Fishburn, London, UK during preparation of this article. The authors were fully responsible for all content and editorial decisions, were involved at all stages of development and have approved the final version.
The page processing charges for this article have been paid by Boehringer Ingelheim.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed.
Both authors contributed to writing and editing the manuscript and read and approved the final version.
Ethics approval and consent to participate
Consent for publication
Martin Kolb reports receipt of grants and personal fees from Boehringer Ingelheim and Roche; personal fees from GlaxoSmithKline, Gilead, AstraZeneca, ProMetic and Genoa; and grants from Actelion, Respivert, the Canadian Institutes of Health Research (MOP-136950), and the Canadian Pulmonary Fibrosis Foundation. Martina Vašáková has received payment for consultancy, lectures and advisory board attendance from Roche and Boehringer Ingelheim and has received research grants from Roche.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 2.Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group. What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018;51(5) pii: 1800692.Google Scholar
- 11.Wijsenbeek M, Kreuter M, Fischer A, Mounir B, Zouad-Lejour L, Wells CD, et al. Non-IPF progressive fibrosing interstitial lung disease (PF-ILD): the patient journey. Am J Respir Crit Care Med. 2018;197:A167.Google Scholar
- 12.Olson AL, Gifford AH, Inase N, Fernández Pérez ER, Suda T. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev. 2018;27(150). pii: 180077.Google Scholar
- 27.Kreuter M, Stansen W, Stowasser S, Schoof N. Impact of lung function decline on health-related quality of life in patients with idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med. 2018;197:A1604. Poster available at: http://ILDPosters2018.com/pdf/ATS_FVCandHRQL_Kreuter.pdf.
- 29.Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007;66(6):754–63.PubMedPubMedCentralCrossRefGoogle Scholar
- 33.Salisbury ML, Gu T, Murray S, Gross BH, Chughtai A, Sayyouh M, et al. Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory. Chest. 2018. https://doi.org/10.1016/j.chest.2018.08.1076 epub ahead of print.
- 45.Ryerson CJ, Kolb M. The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy? Eur Respir J 2018;51(1). pii: 1702420.Google Scholar
- 56.Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PMA, Moodley Y, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J 2017;49. pii: 1601592.Google Scholar
- 57.Snyder L, Neely ML, Hellkamp AS, O’Brien E, de Andrade J, Conoscenti CS, et al. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO registry. Respir Res. in press.Google Scholar
- 77.Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. Rheumatology (Oxford). 2014;53(9):1676–82.CrossRefGoogle Scholar
- 84.Yamakawa H, Hagiwara E, Kitamura H, Yamanaka Y, Ikeda S, Sekine A, et al. Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease. J Thorac Dis. 2017;9(2):362–71.PubMedPubMedCentralCrossRefGoogle Scholar
- 90.Bauer Y, White ES, de Bernard S, Cornelisse P, Leconte I, Morganti A, et al. MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Res 2017;3(1). pii: 00074–2016.Google Scholar
- 91.Todd J, Vinisko R, Neely ML, Overton R, Flaherty KR, Noth I, et al. Peripheral blood matrix metalloproteinase profiling in the multicenter IPF-PRO Registry cohort. Poster presented at the 10th International Colloquium on Lung and Airway Fibrosis (ICLAF), September 2018. Available at http://uspubs-posters.com/iclaf2018/todd.
- 93.Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, et al. Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK trial. BMJ Open Resp Res. 2018;5(1):e000325.PubMedCrossRefGoogle Scholar
- 97.Newton CA, Oldham JM, Ley B, Anand V, Adegunsoye A, Liu G, et al. Telomere length and genetic variant associations with interstitial lung disease progression and survival. Eur Respir J 2019. pii: 1801641 doi: https://doi.org/10.1183/13993003.01641-2018 [Epub ahead of print].
- 102.Juge PA, Borie R, Kannengiesser C, Gazal S, Revy P, Wemeau-Stervinou L, et al. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J. 2017:49(5). https://doi.org/10.1183/13993003.02314-2016.
- 104.Raghu G. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Eur Respir J. 2017;50(4). https://doi.org/10.1183/13993003.01209-2017.
- 105.Flaherty KR, Brown KK, Well AU, Clerisme-Beaty E, Collard HR, Cottin V, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017;4:e000212.PubMedCrossRefGoogle Scholar
- 106.Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS). Clin Exp Rheumatol. 2017;35 Suppl 106(4):75–81.Google Scholar
- 107.Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017;18(1):275.PubMedPubMedCentralCrossRefGoogle Scholar
- 108.Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Resp Res. 2018;5(1):e000289.PubMedCrossRefGoogle Scholar
- 109.Pulmonary Fibrosis Foundation: PFF Patient Registry. https://www.pulmonaryfibrosis.org/medical-community/pff-patient-registry (2016). Accessed 24 October 2018.
- 110.O'Brien EC, Durheim MT, Gamerman V, Garfinkel S, Anstrom KJ, Palmer SM, et al. Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) Registry. BMJ Open Resp Res. 2016;3(1):e000108.Google Scholar
- 111.Ryerson CJ, Tan B, Fell CD, Manganas H, Shapera S, Mittoo S, et al. The Canadian Registry for Pulmonary Fibrosis: design and rationale of a national pulmonary fibrosis registry. Can Respir J. 2016;2016:3562923.Google Scholar
- 113.Kreuter M, Herth FJF, Wacker M, Leidl R, Hellmann A, Pfeifer M, et al. Exploring clinical and epidemiological characteristics of interstitial lung diseases: rationale, aims, and design of a nationwide prospective registry—the EXCITING-ILD registry. Biomed Res Int. 2015;2015:123876.PubMedPubMedCentralGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.